In addition, IRS2 amplification, firstly confirmed in a study of PI3K signaling pathway changes in colorectal cancer (Parsons et al. 2005), has been a vital indicator of sensitivity to targeted therapy in colorectal and lung cancers (Bertotti et al. 2015). Here, PIK3CA is linked to lung carcinoma.